Peptides for Nerve Damage & Neuropathy

How peptide Targets Peptides for Nerve Damage

BPC-157 has the broadest preclinical nerve-repair dataset among research peptides. Rodent studies demonstrate accelerated sciatic nerve crush injury recovery, improved nerve conduction velocity after transection, and functional motor recovery in various peripheral nerve injury models. The proposed mechanisms include upregulation of growth factors (VEGF, EGF, nerve growth factor), modulation of the NO system, and promotion of Schwann cell proliferation — the glial cells essential for peripheral nerve myelination and regeneration. BPC-157 also shows neuroprotective effects against various neurotoxic insults in preclinical models. The limitation is consistent: this is entirely rodent data with no controlled human trials for neuropathy.

Cerebrolysin occupies a different evidence tier. This porcine brain-derived peptide mixture contains biologically active fragments that mimic endogenous neurotrophic factors (BDNF, GDNF, NGF, CNTF). It has been studied in multiple randomized controlled trials for stroke recovery, traumatic brain injury, and Alzheimer's disease — primarily in European and Asian clinical centers. For peripheral neuropathy specifically, cerebrolysin has shown improvements in nerve conduction studies and clinical symptom scores in diabetic neuropathy trials, though the evidence base is smaller than for its stroke indications. It is approved for neurological indications in over 40 countries but not in the United States.

Dihexa is a hexapeptide derivative of angiotensin IV that potently activates the hepatocyte growth factor (HGF)/c-Met receptor system. HGF is a powerful neurotrophic and neuroprotective factor involved in neuronal survival, axonal outgrowth, and synaptogenesis. In preclinical models, dihexa demonstrated extraordinary potency — orders of magnitude more active than BDNF in promoting dendritic spine formation. However, dihexa is at a very early research stage with essentially no human safety or efficacy data. Its extreme potency is both its scientific interest and its primary safety concern, as long-term effects of sustained HGF pathway activation (including theoretical oncogenic risk) are unknown.

Semax, the synthetic ACTH(4-10) analog, upregulates brain-derived neurotrophic factor (BDNF) and modulates neurotrophin signaling. Russian clinical studies report efficacy in ischemic stroke recovery, where neuronal repair mechanisms overlap with peripheral nerve regeneration pathways. BDNF is critical for both central and peripheral nervous system repair. Semax is administered intranasally and has an established safety profile from decades of clinical use in Russia, though Western replication of these findings remains limited.